MEDP

SEC source: 0001567619-21-012618 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,253,370

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012513 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,255,207

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.21 to $183.99. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012512 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,255,207

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.21 to $183.99. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012513 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,267,340

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.035 to $182.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012512 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,267,340

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.035 to $182.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012434 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,276,685

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012433 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,276,685

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012434 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,277,946

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.405. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012433 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,277,946

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.405. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012321 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,286,873

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.685. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012320 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,286,873

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.685. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012321 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,304,286

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $183.20. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012320 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,304,286

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $183.20. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-012190 · doc1.xml · derivative · entry 6

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,400

Underlying: Common Stock · 7,600 shares

Expires 2024-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Each option vested on March 15, 2021.

SEC source: 0001567619-21-012190 · doc1.xml · derivative · entry 5

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,400 shares

Expires 2023-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Each option vested on August 10, 2020.

SEC source: 0001567619-21-012190 · doc1.xml · nonDerivative · entry 4

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,005

F1 · kind: The sales reported on this Form 4 were effected pursuant to a limit order by the Reporting Person.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $178.43 to $179.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012190 · doc1.xml · nonDerivative · entry 3

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were effected pursuant to a limit order by the Reporting Person.

SEC source: 0001567619-21-012190 · doc1.xml · nonDerivative · entry 2

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,005

F1 · kind: The sales reported on this Form 4 were effected pursuant to a limit order by the Reporting Person.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $178.50 to $179.33. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-012190 · doc1.xml · nonDerivative · entry 1

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,405

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were effected pursuant to a limit order by the Reporting Person.

SEC source: 0001567619-21-010623 · doc1.xml · derivative · entry 2

DAVENPORT FRED B JR · CIK 0001181154 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,822

Underlying: Common Stock · 1,822 shares

Expires 2028-05-14

F2 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-21-010620 · doc1.xml · derivative · entry 1

Carley Brian T · CIK 0001677791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,822

Underlying: Common Stock · 1,822 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-21-010621 · doc1.xml · derivative · entry 1

McCarthy Cornelius P. III · CIK 0001750355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,822

Underlying: Common Stock · 1,822 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-21-010622 · doc1.xml · derivative · entry 1

Kraft Robert O. · CIK 0001558592 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,822

Underlying: Common Stock · 1,822 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-21-010619 · doc1.xml · derivative · entry 1

Keating Ashley M. · CIK 0001777217 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,822

Underlying: Common Stock · 1,822 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-21-010616 · doc1.xml · derivative · entry 1

King Tom C · CIK 0001792446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,822

Underlying: Common Stock · 1,822 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-21-008751 · doc1.xml · derivative · entry 2

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,028

Underlying: Common Stock · 23,028 shares

Expires 2026-10-27

F1 · derivative.exercise_date: The Option vests on October 27, 2025, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001567619-21-008749 · doc1.xml · derivative · entry 2

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,230

Underlying: Common Stock · 18,230 shares

Expires 2026-10-27

F1 · derivative.exercise_date: The Option vests on October 27, 2025, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001567619-21-008746 · doc1.xml · derivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,570

Underlying: Common Stock · 57,570 shares

Expires 2029-04-27

F2 · derivative.exercise_date: The Option vests on April 27, 2023, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001567619-21-008748 · doc1.xml · derivative · entry 2

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,028

Underlying: Common Stock · 23,028 shares

Expires 2026-10-27

F1 · derivative.exercise_date: The Option vests on October 27, 2025, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001567619-21-008644 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,319,992

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $188.54 to $195.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-008643 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,319,992

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $188.54 to $195.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-008644 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,340,721

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $187.515 to $191.705. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-008643 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,340,721

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $187.515 to $191.705. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-008541 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,348,526

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $185.25 to $191.62. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-008540 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,348,526

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $185.25 to $191.62. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-008541 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,362,903

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $182.95 to $189.39. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-008540 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,362,903

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $182.95 to $189.39. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-008414 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,378,590

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $185.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-008413 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,378,590

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $185.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-008414 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,396,213

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $183.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-008413 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,396,213

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $183.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-016136 · doc4.xml · nonDerivative · entry 3

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,404,684

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $184.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-21-016131 · doc4.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,404,684

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $184.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-016136 · doc4.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,422,212

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.045 to $190.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-21-016134 · doc4.xml · derivative · entry 6

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,800 shares

Expires 2024-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Each option vested on March 15, 2021.

SEC source: 0000899243-21-016134 · doc4.xml · nonDerivative · entry 4

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,854

F1 · kind: The sales reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.13 to $187.07. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-21-016134 · doc4.xml · nonDerivative · entry 3

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

SEC source: 0000899243-21-016131 · doc4.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,422,212

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.045 to $190.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-016136 · doc4.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,453,482

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.55. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-21-016134 · doc4.xml · derivative · entry 5

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,800

Underlying: Common Stock · 1,200 shares

Expires 2024-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Each option vested on March 15, 2021.